Celltrion Group this year will endeavor to make Remsima-like hits with other biosimliars in the global market, said its chairman Seo Jung-jin.

"2017 is the first year in which Celltrion’s three key biosimilars make their debut in Europe. We will extend the success of Remsima with follow-up products Truxima and Herzuma,” Seo said in a global distributor meeting held in Paris, France last Friday.

Remsima, Celltrion Co.’s first commercially launched biosimilar, recently took the central stage in global markets after Seo began promotion of the product in person by visiting the U.S., Japan and Europe. He is expanding his global network by joining various partner events and meetings, including a Remsima launching event held in Las Vegas in December.

Last Friday, Celltrion held a global strategic meeting with chief executives and representatives from 19 global distributors of Celltrion Healthcare Inc. in Paris. Celltrion Healthcare is a subsidiary responsible for marketing of biologic products produced by Celltrion.

Participants shared ideas for successful launching of Truxima and Herzuma awaiting regulatory approval by the European Medicines Agency (EMA) this year.

“This year is a critical year where we are going to see Remsima further increase its global footprint and launch Truxima and Herzuma. The two new products following Remsima will be distributed through our current partners, and we will come up with more lucrative products in the future to enrich our partnership,” Seo said during the meeting.

“Celltrion Healthcare and Mundipharma will strengthen partnership for segment-targeted marketing and work hard to advance the launch of Truxima and Herzuma and succeed the success of Remsima,” said Anthony Mattessich, chief executive of Mundipharma, during the meeting.

By Shin Chan-ok

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]